Angle Share News (AGL)

Angle Information

Buy AGL Shares
Add AGL to Watchlist
Add AGL to Alert

Share Price Information for Angle (AGL)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 14.00

Bid: 13.50

Ask: 14.50

Change: -0.50 (-3.45%)

Spread: 1.00 (7.407%)

Open: 14.50

High: 14.50

Low: 14.00

Prev. Close: 14.50

Last checked at -

IN BRIEF: Angle to raise GBP20 million through shares placing

Thu, 24th Jun 2021 19:30

Angle PLC - Guildford, England-based liquid biopsy company - Launches a placing to raise gross proceeds of up to GBP20 million at a price of 116 pence each. The company says it will issue 17.2 million shares at a price which represents a discount of 6.8% to the closing mid-market price of its shares of 124.50p on Wednesday. finnCap and WG Partners are acting as joint brokers to the company alongside Beech Hill Securities, which is acting as US broker to the company. Angle says it intends to use the proceeds of the placing to progress commercialisation of the Parsortix system.

Current stock price: 125.00p

Year-to-date change: more than doubled from 47.75p on December 31

By Evelina Grecenko; evelinagrecenko@alliancenews.com

More News

7 Nov 2019 13:50

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

31 Oct 2019 15:38

Angle Submits Positive Test Results For Parsortix System To US FDA

4 Oct 2019 15:17

Angle upbeat on patent grant for prostate cancer blood assessment

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.

4 Oct 2019 08:58

Angle Notes Queen Mary University's European Cancer Prognosis Patent

4 Sep 2019 14:09

Angle Reports Positive Study Results For Parsortix System

(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it

29 Aug 2019 10:57

Angle Ovarian Cancer Testing Platform Study Enrols First Patients

(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study

29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

21 Jun 2019 15:26

Angle upbeat on recent cancer research results

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.

21 Jun 2019 12:56

Angle's Parsortix Successfully Investigates Immunotherapy Target

(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a

5 Jun 2019 13:04

Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study

LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to

31 May 2019 09:53

Angle reveals positive results from latest Parsortix study

(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.

26 Apr 2019 12:48

Angle's Parsortix system used in more groundbreaking research

(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.

26 Apr 2019 12:29

Angle's Parsortix System Used In Further "Groundbreaking" Research

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time

Latest Share Chat

Angle Share News (AGL)

Share Price Information for Angle (AGL)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Angle to raise GBP20 million through shares placing

Login to your account

Quickpicks are a member only feature

Login to your account